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LESS ISMORE
Targeting Vascular Risk Factors in Older Adults
From Polypill to Personalized Prevention
Enrico Mossello, MD, PhD
For many years vascular disease prevention strategies have
been focused on reducing undertreatment, often using a
“one-size-fits-all” approach to increase patient adherence.
The paradigm of this approach has been the proposal of a
polypill targeting multiple
vascular risk factors, a stan-
dard treatment aimed at
maximizing vascular protec-
tion. Conversely, during recent years an increasing emphasis
has been placed on the issue of potential overtreatment, fre-
quently resulting from the same treatment approach in all
patients despite significant individual differences in comor-
bidity and life expectancy. In type 2 diabetes mellitus
(T2DM), data from randomized clinical trials1 have shown
uncertain or negative benefit-risk trade-offs associated with
aggressive treatment of hypertension and hyperglycemia.
These results, added to the well-known exclusion of elderly
individuals with multiple morbidities from nearly all clinical
trials, have informed recent guidelines, which now recom-
mend more moderate targets for treatment of T2DM and
hypertension in older participants, especially those consid-
ered frail or affected by important comorbidities.1
These treatment recommendations raise thepossible strat-
egyof treatmentdeintensification forhighbloodpressure and
hyperglycemia inpatientswithvaluespreviously identified as
optimal and now labeled as low. This issue was addressed by
Sussman and colleagues2 in a large retrospective sample of
older individualswithT2DM(meanage, 78years) fromtheVet-
eransHealthAdministrationactively treated forT2DMorhigh
blood pressure. They found that treatment deintensification
(ie, dosage reduction or drug withdrawal) was performed in
one-quarteror lessofparticipantswith lowbloodpressure (sys-
tolic blood pressure <130 mm Hg or diastolic blood pressure
<65mmHg) or a lowhemoglobin A1c (HbA1c) level (<6.5%) (to
convert to aproportionof total hemoglobin,multiplyby0.01).
Moreover, whether treatment reduction occurred was only
weaklyassociatedwithapatient’sbloodpressureorHbA1c level
and predicted life expectancy, suggesting that physicians are
generally reluctant to deintensify treatment even in condi-
tions thatmakebenefits of therapy limited in comparisonwith
potential harms.
This interpretation is confirmed by a further study from
the Department of Veterans Affairs in the present issue of
JAMA Internal Medicine. Caverly et al3 surveyed a national
sample of health care professionals providing primary care,
showing that almost half of them would not worry about
harms of tight glycometabolic control obtained with an insu-
lin secretagogue in an older patient at high risk for hypogly-
cemia. This approach to therapy was largely explained by
the concern of making the patient’s HbA1c level fall out of
Department of Veterans Affairs performance measures,
which, as the authors point out, have never targeted values
less than 7.0%. Nearly one-quarter of the health care profes-
sionals interviewed would even be concerned about mal-
practice liability risk with deintensification of hypoglycemic
medications.
In keepingwith these data, Sussman and colleagues2 call
for a change in guidelines, qualitymeasures, and clinical per-
formance management that should include recommenda-
tions and incentives to avoid overtreatment. This statement
is alsoconsistentwitha recentanalysisofoutpatientandemer-
gencydepartmentperformancemeasures in theUnitedStates
that shows a lack of measures addressing overuse, especially
regarding treatments.4 Yet, somecaveats shouldbe raised.Al-
though studies ofmore aggressive control of risk factors have
generally failed to show a reduction of cardiovascular events
inT2DM, fewdataexist regarding theprognostic effectofdein-
tensification, especially in patients with good treatment tol-
erance. Conversely, more stringent targets are still recom-
mended, although with a low level of evidence, for younger
patients with a low risk for adverse events.1 In addition, in-
centives for treatmentwithdrawalmight carry a risk of avoid-
ing potentially useful preventive strategies, especially in the
present time of resource constraints. Less is not alwaysmore,
andweshouldnot riskeliminating thebenefitsof therapywhile
attempting to lower the risk.
A proposed stratification of antihypertensive and anti-
diabetic treatment strategies according to patient vulnerabil-
ity is described in the Figure, including issues that should be
further clarified and possible solutions. A first step is repre-
sented by the need for simple but clear indicators of vulner-
ability, which may suggest the need for less-stringent control
of risk factors. According to the limited evidence available, a
less-stringent HbA1c target level in the treatment of diabetes
might be associated with a better prognosis in patients with
T2DM with overt disability,5 older age, and more severe
comorbidity, especially if they are receiving insulin.6 More-
over, in observational studies of individuals without diabe-
tes, antihypertensive treatment leading to lower blood pres-
sure values was associated with greater mortality risk in
elderly nursing home residents7 and a negative effect in par-
ticipants with cognitive impairment8 and slow gait speed.9
These observations should be replicated in large observa-
tional studies. As a further step, appropriate clinical trials on
deintensification of vascular risk factors treatment in spe-
cifically identified vulnerable groups should be designed to
assess the effects of less aggressive control and identify
appropriate targets for intervention.
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In waiting for such evidence, it is reasonable to use avail-
able vulnerability indicators as designators for a more cau-
tious approach to vascular risk factor prevention. In the study
by Sussman et al,2 patients who had the lower frequency of
blood pressure or HbA1c monitoring also had the lowest rate
of treatment discontinuation. This finding suggests that low
values for thesemeasures is not perceived as apotential prob-
lem and, conversely, thatmore strict control, at least initially,
will probably be needed for deintensification of treatment. In
more complex, selected cases, vulnerable patients might be
referred for a comprehensive geriatric assessment, including
risk for falls, hypoglycemia, treatmentnonadherence, and co-
morbidity, to appropriately balance risks and benefits of pre-
ventive treatment. This kind of approach would increase the
numberofclinicalassessments forvulnerable individualsalong
with a possible increase in costs, but this increase could be
counterbalanced by savings from a decreased number of pre-
scriptionsandtheexpectedreductionofadverseevents.There-
fore, clinical performancemeasures coupling treatment dein-
tensification with appropriate clinical assessments and
monitoring seem reasonable to safely discontinue unneces-
sary and potentially harmful treatments while retaining the
benefits of vascular prevention. This approach will be key to
designingeffectivepersonalizedpreventionstrategies forolder
vulnerable subjects.
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Figure. Proposed Stratification of Antihypertensive and Antidiabetic
Treatment in Type 2 DiabetesMellitus According to Patient Vulnerability
Patients with T2DM Vascular risk factors control
Robust
(younger, short
disease duration)
Standard
Vulnerable
Possible vulnerability indicators
Overt disability
Cognitive impairment
Reduced physical performance
More stringent
SBP <130 mm Hg, HbA1c <6.5%
Standard
SBP <140 mm Hg, HbA1c <7.0%
Repeated checks of risk factors
Possible comprehensive geriatric
assessment
Treatment deintensification RCTs
Less stringent
SBP <150 mm Hg, HbA1c <8.0%
?
?
Solid line with arrowhead indicates standard vascular risk control strategy.
Dashed lines with arrowheads indicate possible vascular risk control strategies
for robust and vulnerable patients, with questionmarks pointing out the need
for a choice. Gray box presents the proposed approach for vulnerable
individuals. HbA1c indicates hemoglobin A1c; RCTs, randomized clinical trials;
SBP, systolic blood pressure; and T2DM, type 2 diabetes mellitus. To convert
HbA1c to a proportion of total hemoglobin, multiply by 0.01.
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